Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00888940 · ClinicalTrials.gov registry record · Phase 2
Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery
A Phase 2 study of Surgical Procedures, Operative and Bloodloss, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 2
- Development phase
- 243
- Enrollment target
- 20
- Study locations
NCT00888940 is a Phase 2 study of Surgical Procedures, Operative and Bloodloss that has completed, run by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 243 participants. The trial reports 20 study locations across 2 states.
The verdict
NCT00888940, a Phase 2 study of Surgical Procedures, Operative and Bloodloss, has completed, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 243 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 2 Randomized Double-Blind Active-Controlled Study in Subjects Exposed to Cardio-pulmonary Bypass During Cardiac Surgery at High Risk of Bleeding
Conditions Studied
Interventions
- DRUG Ecallantide
- DRUG Cyklokapron(R)
Study Locations (20)
Other
- Universitaetsklinikum Aachen AoeR - Aachen
- Klinikum Augsburg - Augsburg
- Herz- und Gefaesszentrum Bad Bevensen - Bad Bevensen
- Universitaetsklinikum Bonn - Bonn
- Klinik und Poliklinik fuer Herz- und Thoraxchirurgie der Universitaet zu Koeln - Cologne
- St. Johannes Hospital - Dortmund
- Herzzentrum Dresden GmbH Universitaetsklinik - Dresden
- Universitaetsklinikum Erlangen - Erlangen
- Universitaetsklinikum Frankfurt - Frankfurt
- Universitaetsklinikum Freiburg - Freiburg im Breisgau
- Universitaetsmedizin Goettingen - Göttingen
- Universitaetsklinikum Halle (Saale) - Halle
- Universitaeres Herzzentrum Hamburg GmbH - Hamburg
- Universitaetsklinikum Heidelberg - Heidelberg
- Herzzentrum Leipzig GmbH - Leipzig
- Klinikum der Stadt Ludwigshafen gGmbH - Ludwigshafen
- Klinik fuer Herzchirurgie des Universitaetsklinikum SH - Lübeck
- Deutsches Herzzentrum Muenchen - Munich
- HELIOS Klinik Wuppertal - Wuppertal
Alabama
- Cardio-Thoracic Surgeons PC - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)42 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00888940
The ClinicalTrials.gov registry entry for NCT00888940 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 42 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Surgical Procedures, Operative appearing as the primary indexed condition, and to 2 interventions - of which Ecallantide is the first listed.
NCT00888940 reports 20 study locations spanning 2 distinct geographic areas - top geographies include Other, Alabama.
Frequently Asked Questions
What is clinical trial NCT00888940 about?
NCT00888940 is a clinical study titled "Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery". A Phase 2 Randomized Double-Blind Active-Controlled Study in Subjects Exposed to Cardio-pulmonary Bypass During Cardiac Surgery at High Risk of Bleeding
What is the current status of trial NCT00888940?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 243 participants. The study started on 2009-06. Estimated completion is 2010-01.
What conditions does trial NCT00888940 study?
This clinical trial studies the following conditions: Surgical Procedures, Operative, Bloodloss.
What interventions are being tested in trial NCT00888940?
The interventions under investigation include: Ecallantide (DRUG), Cyklokapron(R) (DRUG).
Who is sponsoring clinical trial NCT00888940?
This trial is sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00888940 being conducted?
This trial has 20 study locations across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Surgical Procedures, Operative
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.